Moderna shares slide on cancer vaccine data with Merck
FROM THE WIRE · FINANCE.YAHOO.COM
Moderna and Merck’s cancer vaccine reduced the risk of melanoma recurrence or death by 42%, but investors questioned its potential across other cancers. Continue Reading
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishInvestors question the vaccine's potential beyond melanoma, weighing on the shares.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Moderna and Merck's cancer vaccine cuts the risk of melanoma recurrence or death by 42%.
- 02Investors questioned its potential across other cancers.
- 03The stock saw panic selling.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Moderna, Inc.203.62 USD+2.02%today +0.49%Negative Merck & Co., Inc.145.06 USD+0.75%today -1.48%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets